U.S. FDA Accepts for Review the Biologics License Application for Pfizer ’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents

If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine NEW YORK--(BUSINESS WIRE) December 28, 2022 -- Pfizer Inc. (NYSE:PFE) today...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials